• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Little Miss Hannah Foundation

Support for Families of Children Diagnosed with Rare, Life-Limiting, or Complex Medically Conditions. Childhood Rare Disease Advocacy.

Make a Donation Volunteer Apply for Services
  • About Us
    • Our Mission
    • Meet our Team
    • Photos/Videos
      • Photos
      • Videos
    • Latest News
    • Our Impact Results
  • Hannah’s Story
  • Programs
    • Medical-Therapy Equipment Assistance Program
    • College Scholarship
    • Childhood Rare Disease Advocacy
    • Family Support and Activities
  • 2022 Tee Up FORE Rare Golf
  • 2023 Vegas Rare 5K
  • Get Help
    • Become a LMHF Family
    • Make-A-Wish Referrals
    • Resources
  • Get Involved
  • Contact us

June 26, 2012 by Carrie Ostrea

Bipartisan Action Offers Rare Disease Patients Hope, NORD Says

Washington DC—–Millions of Americans who have serious rare diseases and no treatment may face a brighter future as a result of a bill approved today by the U.S. Senate, according to the National Organization for Rare Disorders (NORD).

“We salute the Senate for decisive and bipartisan action in approving the FDA Safety and Innovation Act (S. 3187),” said Peter L. Saltonstall, president and CEO of NORD. “And we applaud the House of Representatives for approving in a similarly bipartisan manner the House version of this bill last week.”

Saltonstall said the legislation, which now goes to President Obama for his signature, provides broad-ranging and innovative measures to speed the development of safe and effective treatments for people who desperately need them.

“Only about 250 of the nearly 7,000 diseases considered rare in the U.S. have therapies,” he said. “But treatments are desperately needed because most rare diseases are serious, many are life-threatening, and about two-thirds of the patients are children.”

He added that “NORD and its members have worked long and hard to raise awareness of the challenges of living with rare diseases. We are grateful for the hard work and thoughtful deliberation that both the House and Senate have brought to this process.”

Among others, some features of the bill that Saltonstall said were especially important to NORD and the rare disease patient community include:

  • enhancing accelerated patient access to new medical treatments
  • encouraging the development of Humanitarian Use Devices, or medical devices for small patient populations
  • providing for accelerated development of “breakthrough therapies” — or ones that show early promise
  • enhanced consultation with rare disease medical experts and
  • a rare pediatric disease priority review voucher incentive program

The bill approved by the Senate today and the one approved by the House last week are the result of a process that has been underway for nearly two years and for which NORD has provided significant input, the reauthorization of the Prescription Drug User Fee Act (PDUFA). This legislation, which authorizes the Food and Drug Administration (FDA) to collect user fees from companies seeking to have products reviewed, must be reauthorized every five years.

———————————-

Contact:  Mary Dunkle (mdunkle@rarediseases.org)
Vice President, Communications, NORD

Filed Under: Blog Tagged With: Rare Disease News

Primary Sidebar

Our Upcoming Event!


Tee Up FORE Rare 2022
 

Featured Programs


Medical and Therapy Equipment Grant Program

Site Info

  • About Us
  • Our Mission
  • Latest News
  • Hannah’s Story
  • Programs

Get Involved!

  • Become a LMHF Family
  • Upcoming Events
  • Donate
  • Volunteer
  • Rare Disease Advocacy

Contact Us

10624 S. Eastern Avenue, Suite A-847
Henderson, NV 89052
Phone: (702) 608-2488
Fax: (702) 541-9957

Privacy Policy

Connect With Us

  • Email
  • Facebook
  • Instagram
  • Twitter

Copyright © 2023· Little Miss Hannah Foundation · Site By New Wave Media Design
Little Miss Hannah Foundation is a 501(c)(3) tax-exempt nonprofit corporation, EIN# 45-3993921